Gamida Cell Ltd. (NASDAQ:GMDA) Q1 2023 Results Conference Call May 15, 2023 4:30 PM ET

Company Participants

Mike Kuczkowski - Corporate Communications

Abbey Jenkins - President and CEO

Michele Korfin - COO and Chief Commercial Officer

Ronit Simantov - Chief Medical Officer and Scientific Officer

Shai Lankry - CFO

Conference Call Participants

Edward Tenthoff - Piper Sandler

Gil Blum - Needham & Company

Vernon Bernardino - H.C. Wainwright

Mark Breidenbach - Oppenheimer

Operator

Ladies and gentlemen, thank you for standing by. Welcome to the Gamida Cell’s Conference Call for the First Quarter 2023 Financial Results. My name is Catherine and I’ll be your operator for today’s call. Please be advised that this call is being recorded at Gamida Cell’s request.

I would like to introduce your host for today’s conference, Mike Kuczkowski of Gamida Cell Corporate Communications. Mike, please go ahead.

Mike Kuczkowski

Thank you, Catherine, and good evening, everyone. Welcome to today’s call during which we will provide an update on the Company and review our financial results for the first quarter of 2023. Earlier today, we issued a press release summarizing our financial results and providing a business update which is available on our website at www.gamida-cell.com.

Here with me on our call today are Abbey Jenkins, President and Chief Executive Officer; Michele Korfin, Chief Operating Officer and Chief Commercial Officer; Ronit Simantov, Chief Medical Officer and Scientific Officer; and Shai Lankry, Chief Financial Officer.

Today’s call will follow a slightly different format than we have recently as we just had our Omisirge approval call on April 17th. Abbey and Shai will share brief updates. Michele and Ronit will be available for the Q&A.

Before I begin, I want to remind everyone that during the call, we may make forward-looking statements about our future expectations and plans, including with respect to the timing of and initiation and progress of and data reported from preclinical and clinical trials of our products and product candidates, regulatory filings, commercialization planning efforts to potentially life-saving or curative therapeutic and commercial potential of Gamida Cell’s product, Omisirge and product candidate, GDA-201 and our expectations regarding our projected cash, cash equivalents and investments to be used for operating activities.

Our actual results may differ materially from what we project today due to a number of important factors, the scope progress and expansion of our clinical trials, and impacts to the cost thereof, clinical scientific, regulatory and technical developments, those inherent in the process of developing and commercializing product candidates that are safe and effective for use as human therapeutics and in the endeavor of building a business around such product candidates, as well as those considerations described in the Risk Factors section of our most recent annual report on Form 10-K and other filings that we may make with the SEC from time to time. These forward-looking statements represent our views only as of today, and we caution you that we may not update them in the future, whether as a result of new information or future events, except as required by applicable law.